Covid 19: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Grants and Contracts Details

StatusActive
Effective start/end date2/5/2112/8/22

Funding

  • Janssen Vaccines and Prevention BV: $1,051,327.00